Zimmer Partners LP Sells 154,200 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Zimmer Partners LP lessened its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 73.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,900 shares of the company's stock after selling 154,200 shares during the period. Zimmer Partners LP owned approximately 0.10% of Structure Therapeutics worth $1,543,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd increased its position in shares of Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after purchasing an additional 553 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after buying an additional 455 shares in the last quarter. Assetmark Inc. grew its position in Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after acquiring an additional 953 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Structure Therapeutics by 673.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock worth $111,000 after acquiring an additional 3,549 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter worth approximately $113,000. Institutional investors own 91.78% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. Citigroup assumed coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They set a "buy" rating and a $60.00 price target for the company. Finally, HC Wainwright decreased their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $79.86.

Structure Therapeutics Stock Performance

NASDAQ:GPCR traded down $0.10 during midday trading on Monday, reaching $24.55. 267,802 shares of the stock traded hands, compared to its average volume of 932,263. The stock has a market capitalization of $1.41 billion, a P/E ratio of -33.18 and a beta of -1.69. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $62.74. The company has a fifty day moving average of $21.53 and a 200 day moving average of $25.85.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). On average, analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.